Global Radiopharmaceutical Theranostics & Targeted Alpha Therapy Market — Intelligence Report

The global radiopharmaceutical theranostics and targeted alpha therapy market is entering a structural growth phase, shifting from a specialist nuclear medicine segment into a core oncology modality. Nexvora Intelligence estimates the 2025 market at approximately $•••, including therapeutic radiopharmaceuticals, theranostic imaging agents, radioligand therapy infrastructure, isotope-linked services, and early commercial targeted alpha therapy activity. Growth is being driven by validated clinical adoption in prostate cancer and neuroendocrine tumors, expanding radiotracer availability, and a rapidly widening pipeline across solid tumors and hematologic malignancies.

The market’s defining feature is the convergence of diagnostics, therapy, and patient-selection economics. Theranostic models using matched imaging and therapeutic agents are creating more predictable treatment pathways than conventional systemic oncology approaches, supporting higher confidence in patient eligibility, dosimetry planning, and response tracking. This is strengthening payer acceptance where clinical benefit is clear, while also raising the operational bar for hospitals, cancer centers, and nuclear medicine networks.

Targeted alpha therapy represents the highest-growth sub-segment, albeit from a smaller commercial base. Nexvora Intelligence models targeted alpha therapy revenue at roughly $•••–••• billion in 2025, with the potential to reach $•••–••• billion by 2032 if late-stage programs convert and isotope supply constraints are progressively resolved. Alpha emitters are attracting significant strategic attention because of their high linear energy transfer, short path length, and potential utility in micrometastatic or treatment-resistant disease settings.

Commercial execution will be constrained less by demand and more by manufacturing, isotope availability, logistics, and treatment-center readiness. The market requires tightly coordinated production runs, quality control, radiochemistry capabilities, cold-kit or generator systems in select use cases, specialized distribution, radiation safety workflows, and trained multidisciplinary clinical teams. As a result, vertically integrated models and privileged access to isotopes are emerging as decisive competitive advantages.

Nexvora Intelligence developed this market opening using proprietary bottom-up and top-down modeling across therapeutic radiopharmaceutical sales, theranostic imaging utilization, targeted alpha therapy commercialization, isotope supply capacity, clinical pipeline probability, and treatment-center adoption curves.

The estimates incorporate modeled assumptions for procedure volumes, average net realized therapy pricing, regional reimbursement maturity, radiopharmacy capacity, isotope availability, indication expansion, and expected regulatory conversion across late-stage assets.

Because no external evidence was retrieved for this request, all figures are Nexvora Intelligence modeled estimates and should be interpreted as directional market ranges rather than externally sourced statistics.

Forecasts are scenario-weighted to reflect clinical development risk, manufacturing scale-up constraints, nuclear medicine workforce limitations, and variability in payer adoption across major oncology markets.